Athena Athena

X
[{"orgOrder":0,"company":"Arctos Medical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients with Severe Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Arctos Medical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of Optogenetics-based AAV gene therapy as the basis of successful therapeutics.

            Lead Product(s): Optogenetics-based AAV Gene Therapy

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition September 21, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY